Large scale collection of PK–PD observations should be pursued and encouraged for both novel and established critical drugs. Pharmaceutical company should be pressurized to release and publish their data in timely fashion and clinical laboratories in the public health service should complement this effort through multicentre research collaborations. Children and old people, often neglected during drug development, deserve such observational PK–PD studies.